Related Experiment Videos
[Humanized antibodies as therapeutics]
Dominique Bellet1, Virginie Dangles-Marie
1UMR 8149 CNRS, IFR 71, Université René Descartes, Paris 5, Faculté des Sciences Pharmaceutiques et Biologiques de Paris, 4, avenue de l'Observatoire, 75006 Paris, France. dominique.bellet@univ-paris5.fr
Medecine Sciences : M/S
|December 6, 2005
Summary
Nine humanized antibodies are FDA-approved for treating diseases like cancer and MS. This review covers antibody engineering techniques, their effectiveness, adverse effects, and future improvements for humanized antibody therapies.
Area of Science:
- Biotechnology and Immunology
- Therapeutic Antibody Engineering
Context:
- Since 1997, the U.S. Food and Drug Administration (FDA) has approved nine humanized antibodies for clinical use.
- These therapeutic antibodies target a range of conditions, including cancers, autoimmune diseases, and transplant rejection.
Purpose:
- To review current techniques for engineering humanized antibodies, including SDRs (single desired regions) and CDRs (complementarity-determining regions) grafting.
- To highlight the therapeutic efficacy and potential adverse effects of approved humanized antibodies.
- To explore future strategies for enhancing humanized antibody effectiveness, reducing immunogenicity, and lowering production costs.
Summary:
- The review details antibody engineering methods, focusing on SDRs and CDRs grafting.
- Examines the clinical success of antibodies like Mylotarg, Herceptin, and Xolair, while noting the severe adverse events associated with Tysabri.
- Discusses realistic future directions for improving humanized antibody therapies.
Impact:
- Provides insights into the development and application of humanized antibodies in medicine.
- Underscores the balance between therapeutic benefits and risks in antibody-based treatments.
- Offers a forward-looking perspective on advancing antibody engineering for improved patient outcomes.